U
AVEO

UBS’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

UBS’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-350
Closed -$6K – 11018
2013
Q4 		$6K Sell
350
-630
-64% -$12.6K ﹤0.01% 9474
2013
Q3 		$20K Sell
980
-550
-36% -$12.6K ﹤0.01% 8078
2013
Q2 		$38K Buy
+1,530
New +$65.4K ﹤0.01% 7102

Other funds holding AVEO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS's AVEO Position: Q3 2014 in Review

UBS increased its AVEO Pharmaceuticals, Inc. (AVEO) stake by 460% in Q3 2014, buying an estimated $5.85K and bringing the position to 560 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #9339.

UBS first reported a position in AVEO in Q2 2013 and has held it in 6 quarters since. The position peaked at $40K in Q4 2013. 55 funds tracked by Wall St. Rank hold AVEO as of Q3 2014.

  • UBS held 560 shares of AVEO Pharmaceuticals, Inc. worth $6K as of Q3 2014.
  • UBS bought 460 AVEO Pharmaceuticals, Inc. shares in Q3 2014, an estimated $5.85K.
  • AVEO Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9339 holding.
  • UBS first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's AVEO Pharmaceuticals, Inc. position peaked at $40K in Q4 2013.
  • 55 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.